Abstrakt

Przypisy

• 1. Ali R., Cusi K.: New diagnostic and treatment approaches in non–alcoholic fatty liver disease (NAFLD). Ann. Med., 2009; 41: 265-278
  Google Scholar
• 2. Aydin S.: Presence of adropin, nesfatin-1, apelin-12, ghrelins andsalusins peptides in the milk, cheese whey and plasma of dairy cows.Peptides, 2013; 43: 83-87
  Google Scholar
• 3. Aydin S., Kuloglu T., Aydin S.: Copeptin, adropin and irisin concentrationsin breast milk and plasma of healthy women and thosewith gestational diabetes mellitus. Peptides, 2013; 47: 66-70
  Google Scholar
• 4. Aydin S., Kuloglu T., Aydin S., Eren M.N., Yilmaz M., Kalayci M.,Sahin I., Kocaman N., Citil C., Kendir Y.: Expression of adropin in ratbrain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induceddiabetes. Mol. Cell. Biochem., 2013; 380: 73-81
  Google Scholar
• 5. Aydin S., Kuloglu T., Aydin S., Kalayci M., Yilmaz M., Ҫakmak T.,Eren M.N.: Elevated adropin: a candidate diagnostic marker for myocardialinfarction in conjunction with troponin-I. Peptides, 2014;58: 91-97
  Google Scholar
• 6. Baszczuk A., Kopczyński Z., Thielemann A.: Dysfunkcja śródbłonkanaczyniowego u chorych na pierwotne nadciśnienie tętniczez hiperhomocysteinemią. Postępy Hig. Med. Dośw., 2014; 68: 91-100
  Google Scholar
• 7. Buckley B.S., Harreiter J., Damm P., Corcoy R., Chico A., SimmonsD., Vellinga A., Dunne F., DALI Core Investigator Group: Gestationaldiabetes mellitus in Europe: prevalence, current screening practiceand barriers to screening. A review. Diabet. Med., 2012; 29: 844-854
  Google Scholar
• 8. Butler A.A., Tam C.S., Stanhope K.L., Wolfe B.M., Ali M.R., O’KeeffeM., St-Onge M.P., Ravussin E., Havel P.J.: Low circulating adropinconcentrations with obesity and aging correlate with risk factorsfor metabolic disease and increase after gastric bypass surgery inhumans. J. Clin. Endocrinol. Metab., 2012; 97: 3783-3791
  Google Scholar
• 9. Celik A., Balin M., Kobat M.A., Erdem K., Baydas A., Bulut M., AltasY., Aydin S., Aydin S.: Deficiency of a new protein associated with cardiacsyndrome X; called adropin. Cardiovasc. Ther., 2013; 31: 174-178
  Google Scholar
• 10. Celik E., Yilmaz E., Celik O., Ulas M., Turkcuoglu I., Karaer A.,Simsek Y., Minareci Y., Aydin S.: Maternal and fetal adropin levelsin gestational diabetes mellitus. J. Perinat. Med., 2013; 41: 375-380
  Google Scholar
• 11. Cui X.Y., Hu Q.D., Tekaya M., Shimoda Y., Ang B.T., Nie D.Y., SunL., Hu W.P., Karsak M., Duka T., Takeda Y., Ou L.Y., Dawe G.S., Yu F.G.,Ahmed S., et al.: NB-3/Notch1 pathway via Deltex1 promotes neuralprogenitor cell differentiation into oligodendrocytes. J. Biol. Chem.,2004; 279: 25858-25865
  Google Scholar
• 12. Dec M., Bartoszek E., Mosiewicz J.: Obturacyjny bezdech sennya śródbłonek naczyniowy. Czy dysponujemy komórkowymi markeramidysfunkcji śródbłonka? Nowa Med., 2013; 4: 165-167
  Google Scholar
• 13. Demircelik B., Cakmak M., Nazli Y., Gurel O.M., Akkaya N., CetinM., Cetin Z., Selcoki Y., Kurtul A., Eryonucu B.: Adropin: a newmarker for predicting late saphenous vein graft disease after coronaryartery bypass grafting. Clin. Invest. Med., 2014; 37: E338-E344
  Google Scholar
• 14. Gao S., McMillan R.P., Jacas J., Zhu Q., Li X., Kumar G.K., CasalsN., Hegardt F.G., Robbins P.D., Lopaschuk G.D., Hulver M.W., ButlerA.A.: Regulation of substrate oxidation preferences in muscle by thepeptide hormone adropin. Diabetes, 2014; 63: 3242-3252
  Google Scholar
• 15. Gao S., McMillan R.P., Zhu Q., Lopaschuk G.D., Hulver M.W., ButlerA.A.: Therapeutic effects of adropin on glucose tolerance andsubstrate utilization in diet-induced obese mice with insulin resistance.Mol. Metab., 2015; 4: 310-324
  Google Scholar
• 16. Gozal D., Kheirandish-Gozal L., Bhattacharjee R., Molero-RamirezH., Tan H.L., Bandla H.P.: Circulating adropin concentrations inpediatric obstructive sleep apnea: potential relevance to endothelialfunction. J. Pediatr., 2013; 163: 1122-1126
  Google Scholar
• 17. Grzelak T., Janicka E., Kramkowska M., Walczak M., CzyżewskaK.: Cukrzyca ciążowa – skutki niewyrównania i podstawy regulacjiglikemii. Now. Lek., 2013; 82: 163-169
  Google Scholar
• 18. Kuhla A., Hahn S., Butschkau A., Lange S., Wree A., Vollmar B.:Lifelong caloric restriction reprograms hepatic fat metabolism inmice. J. Gerontol. A. Biol. Sci. Med. Sci., 2014; 69: 915-922
  Google Scholar
• 19. Kumar K.G., Trevaskis J.L., Lam D.D., Sutton G.M., Koza R.A.,Chouljenko V.N., Kousoulas K.G., Rogers P.M., Kesterson R.A., ThearleM., Ferrante A.W. Jr, Mynatt R.L., Burris T.P., Dong J.Z., Halem H.A.,et al.: Identification of adropin as a secreted factor linking dietarymacronutrient intake with energy homeostasis and lipid metabolism.Cell. Metab., 2008; 8: 468-481
  Google Scholar
• 20. Kumar K.G., Zhang J., Gao S., Rossi J., McGuinness O.P., HalemH.H., Culler M.D., Mynatt R.L., Butler A.A.: Adropin deficiency is associatedwith increased adiposity and insulin resistance. Obesity,2012; 20: 1394-1402
  Google Scholar
• 21. Lian W., Gu X., Qin Y., Zheng X.: Elevated plasma levels of adropinin heart failure patients. Intern. Med., 2011; 50: 1523-1527
  Google Scholar
• 22. Lovren F., Pan Y., Quan A., Singh K.K., Shukla P.C., Gupta M., Al–Omran M., Teoh H., Verma S.: Adropin is a novel regulator of endothelialfunction. Circulation, 2010; 122: S185-S192
  Google Scholar
• 23. Obońska K., Grąbczewska Z., Fisz J.: Ocena czynności śródbłonkanaczyniowego – gdzie jesteśmy, dokąd zmierzamy? Fol. Card. Exc.,2010; 5: 292-297
  Google Scholar
• 24. Partridge C.G., Fawcett G.L., Wang B., Semenkovich C.F., CheverudJ.M.: The effect of dietary fat intake on hepatic gene expressionin LG/J and SM/J mice. BMC Genomics, 2014; 15: 99
  Google Scholar
• 25. Piegza M., Pudlo R., Badura-Brzoza K., Hese R.T.: Kardiologicznyzespół X w ujęciu psychosomatycznym. Psychiatr. Pol., 2008;42: 229-236
  Google Scholar
• 26. Qiu X., He J.R., Zhao M.G., Kuang Y.S., Xu S.Q., Zhang H.Z., Hu S.P.,Chen J., Xia H.M.: Relationship between human cord blood adropinlevels and fetal growth. Peptides, 2014; 52: 19-22
  Google Scholar
• 27. Ryu R.J., Hays K.E., Hebert M.F.: Gestational diabetes mellitusmanagement with oral hypoglycemic agents. Semin, Perinatol., 2014;38: 508-515
  Google Scholar
• 28. Sakurai K., Toyoshima M., Ueda H., Matsubara K., Takeda Y., KaragogeosD., Shimoda Y., Watanabe K.: Contribution of the neural cell recognition molecule NB-3 to synapse formation between parallelfibers and Purkinje cells in mouse. Dev. Neurobiol., 2009; 69: 811-824
  Google Scholar
• 29. Sayın O., Tokgöz Y., Arslan N.: Investigation of adropin and leptinlevels in pediatric obesity-related nonalcoholic fatty liver disease.J. Pediatr. Endocrinol. Metab., 2014; 27: 479-484
  Google Scholar
• 30. Sena C.M., Pereira A.M., Seiça R.: Endothelial dysfunction –a major mediator of diabetic vascular disease. Biochim. Biophys.Acta, 2013; 1832: 2216-2231
  Google Scholar
• 31. Sobstyl M., Tkaczuk-Włach J., Sobstyl J., Jakiel G.: Zespół metabolicznya zespół policystycznych jajników. Przegl. Menopauz.,2011; 10: 74-78
  Google Scholar
• 32. St-Onge M.P., Shechter A., Shlisky J., Tam C.S., Gao S., RavussinE., Butler A.A.: Fasting plasma adropin concentrations correlate withfat consumption in human females. Obesity, 2014; 22: 1056-1063
  Google Scholar
• 33. Takeda Y., Akasaka K., Lee S., Kobayashi S., Kawano H., MurayamaS., Takahashi N., Hashimoto K., Kano M., Asano M., Sudo K., IwakuraY., Watanabe K.: Impaired motor coordination in mice lacking neuralrecognition molecule NB-3 of the contactin/F3 subgroup. J. Neurobiol.,2003; 56: 252-265
  Google Scholar
• 34. Topuz M., Celik A., Aslantas T., Demir A.K., Aydin S., Aydin S.:Plasma adropin levels predict endothelial dysfunction like flowmediateddilatation in patients with type 2 diabetes mellitus. J. Investig.Med., 2013; 61: 1161-1164
  Google Scholar
• 35. Tousoulis D., Kampoli A.M., Tentolouris C., Papageorgiou N.,Stefanadis C.: The role of nitric oxide on endothelial function. Curr.Vasc. Pharmacol., 2012; 10: 4-18
  Google Scholar
• 36. van den Oever I.A., Raterman H.G., Nurmohamed M.T., SimsekS.: Endothelial dysfunction, inflammation, and apoptosis in diabetesmellitus. Mediators Inflamm., 2010; 2010: 792393
  Google Scholar
• 37. Widlansky M.E., Gokce N., Keaney J.F.Jr., Vita J.A.: The clinicalimplications of endothelial dysfunction. J. Am. Coll. Cardiol., 2003;42: 1149-1160
  Google Scholar
• 38. Wong C.M., Wang Y., Lee J.T., Huang Z., Wu D., Xu A., Lam K.S.:Adropin is a brain membrane-bound protein regulating physical activityvia the NB-3/Notch signaling pathway in mice. J. Biol. Chem.,2014; 289: 25976-25986
  Google Scholar
• 39. Wu L., Fang J., Chen L., Zhao Z., Luo Y., Lin C., Fan L.: Low serumadropin is associated with coronary atherosclerosis in type 2 diabeticand non-diabetic patients. Clin. Chem. Lab. Med., 2014; 52: 751-758
  Google Scholar
• 40. Yildirim B., Celik O., Aydin S.: Adropin: a key component andpotential gatekeeper of metabolic disturbances in policystic ovariansyndrome. Clin. Exp. Obstet. Gynecol., 2014; 41: 310-312
  Google Scholar
• 41. Yu H.Y., Zhao P., Wu M.C., Liu J., Yin W.: Serum adropin levelsare decreased in patients with acute myocardial infarction. Regul.Pept., 2014; 190-191: 46-49
  Google Scholar
• 42. Zhang C., Zhao L., Xu W., Li J., Wang B., Gu X., Chen. J.: Correlationof serum adropin level with coronary artery disease. ZhonghuaYi Xue Za Zhi, 2014; 94: 1255-1257
  Google Scholar

Pełna treść artykułu